Register Now - Unlocking Longitudinal Patient-Reported Outcomes: The Untapped Value of Specialty Pharmacyocking
|Articles|March 24, 2015

Biomedical Systems Announces Affiliation With the ePRO Consortium

(St. Louis, March 24, 2015) – Biomedical Systems, a premier global provider of centralized diagnostic services, announced its affiliation with the Electronic Patient-Reported Outcome (ePRO) Consortium, a program run by the Critical Path Institute (C-Path). 

 Biomedical Systems joined the ePRO Consortium on Jan. 1 and will collaborate with the group’s 10 other members to advance the quality, practicality and acceptance of electronic data capture (EDC) methods used in clinical trials for PRO endpoint assessment.

 “Clinical outcome assessments are becoming more important in clinical trials to determine whether a drug has demonstrated a treatment benefit,” said Timothy Barrett, chief operating officer at Biomedical Systems. “By joining the ePRO Consortium, Biomedical Systems will contribute in a non-competitive and neutral environment to improve the quality of data collection methods for clinical outcomes assessments.”

 With this new partnership, Biomedical Systems reinforces its dedication to the advancement of ePRO to increase the quality of data for electronic data capture. Biomedical Systems’ second generation ePRO platform supports home, site and Web-based systems to collect timely, high-quality data for clinical trials worldwide.

 C-Path is a nonprofit, public-private partnership with the Food and Drug Administration (FDA) and is dedicated to bringing scientists from the FDA, industry and academia together to improve the drug development and regulatory process for medical products. Created in 2011, C-Path established the ePRO Consortium in cooperation with firms that provide technologies and services for capturing patient-reported outcome (PRO) endpoints.

 “We look forward to the new relationships and opportunities our membership in the ePRO Consortium will create for our team and our industry,” said Barrett.


Related to this article

Where AI Leads in Trial Design—and Where Humans Still Need To
In this video interview, Claire Riches, VP of clinical solutions at Citeline, makes the case for AI as a sophisticated strategic advisor in trial design while arguing that humans must remain in the lead—especially when factors the model can't fully account for are at stake.